Please Wait...

Bioclinica launches OnPoint Direct

Clinical Trial Management System (CTMS) for the mid-market and CRO sectors

May 25, 2016

Bioclinica®, Inc., a specialty clinical trials technology and services provider, today introduced OnPoint Direct, a Clinical Trial Management System (CTMS) geared toward mid-market biopharma and Contract Research Organizations (CROs). OnPoint Direct offers a cost-friendly pricing structure that empowers organizations to adopt a full-featured clinical trial management solution without the complex configuration, capital investment or perpetual licensing models customary of other systems.

“We recognize that some organizations run fewer studies, so we created a purpose-built CTMS just for them,” said Bioclinica’s Vice President of Product Management, eHealth Solutions, Ron Burns. OnPoint Direct is a SaaS-based rapid start version of Bioclinica’s OnPoint CTMS, which is used by large pharma companies and CROs around the globe to manage their clinical trials. “Bioclinica now provides organizations with a premier end-to-end study management tool that takes them from rapid study start-up, to study conduct, and on through to study close-out with efficiencies built into every step of the process,” Burns said.

OnPoint Direct is an out-of-the-box solution that shares all of the same core functionality as the original OnPoint, but with streamlined configuration, slashing ramp-up time and investment. The SaaS-based offering is delivered through Bioclinica’s secure eHealth Cloud™, which leverages the Bioclinica Cloud Transformation Gateway™, a secure standards-based integration exchange that connects its eClinical Platform to innovative third-party applications and industry data banks.

“Organizations can now get studies up and running in a matter of weeks compared to several months,” Burns said. “With OnPoint Direct we focused on workflows people are using every day, like those related to Microsoft Word, Excel, Outlook and SharePoint.  OnPoint Direct seamlessly integrates with this suite, creating a familiar and comfortable working environment.” The approach reduces training time and speeds adoption.

To kick-off the new OnPoint Direct offering, Bioclinica will be conducting demonstrations in its exhibit at the DIA Annual Meeting to be held on June 26-30 in Philadelphia. One of Bioclinica’s CTMS experts, Lynn Fraser, is participating in a panel discussion about using CTMS to facilitate collaboration.

Find out more about Bioclinica and its eHealth Solutions at www.Bioclinica.com, and on the Trial Blazers blog at http://www.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica

About Bioclinica
Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (Yesterday)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (2 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (4 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (4 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (4 days ago)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (4 days ago)

Latest Blogs: